Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors
出版年份 2021 全文链接
标题
Dual targeting of CTLA-4 and CD47 on Treg cells promotes immunity against solid tumors
作者
关键词
-
出版物
Science Translational Medicine
Volume 13, Issue 605, Pages eabg8693
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2021-08-05
DOI
10.1126/scitranslmed.abg8693
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
- (2020) Wenyan Zhong et al. BMC GENOMICS
- Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
- (2020) Linlin Ma et al. JOURNAL OF NANOBIOTECHNOLOGY
- Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis
- (2019) Jian Qiao et al. CANCER CELL
- Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding
- (2019) Robyn J. Puro et al. MOLECULAR CANCER THERAPEUTICS
- A novel bispecific antibody fusion protein co-targeting EGFR and CD47 with enhanced therapeutic index
- (2018) Yun Yang et al. BIOTECHNOLOGY LETTERS
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
- (2018) Xinyi Guo et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
- (2018) Xiaojuan Liu et al. Cell Reports
- Lineage tracking reveals dynamic relationships of T cells in colorectal cancer
- (2018) Lei Zhang et al. NATURE
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
- (2018) Ranjana Advani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
- (2017) Frederick Arce Vargas et al. IMMUNITY
- SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
- (2017) Jun Chen et al. NATURE
- Localized CD47 blockade enhances immunotherapy for murine melanoma
- (2017) Jessica R. Ingram et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural basis of a novel heterodimeric Fc for bispecific antibody production
- (2017) Hudie Wei et al. Oncotarget
- Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy
- (2016) Ashley E. Mahne et al. CANCER RESEARCH
- SIRP -Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells
- (2016) E. C. Piccione et al. CLINICAL CANCER RESEARCH
- TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding
- (2016) Penka S. Petrova et al. CLINICAL CANCER RESEARCH
- ICOS+Foxp3+TILs in gastric cancer are prognostic markers and effector regulatory T cells associated withHelicobacter pylori
- (2016) Hirotsugu Nagase et al. INTERNATIONAL JOURNAL OF CANCER
- CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer
- (2016) Kipp Weiskopf et al. JOURNAL OF CLINICAL INVESTIGATION
- Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
- (2016) Tilman Schlothauer et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- The Interaction Between Signal Regulatory Protein Alpha (SIRPα) and CD47: Structure, Function, and Therapeutic Target
- (2013) A. Neil Barclay et al. Annual Review of Immunology
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
- (2013) Geok Choo Sim et al. JOURNAL OF CLINICAL INVESTIGATION
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response
- (2013) D. Tseng et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineered SIRP Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
- (2013) K. Weiskopf et al. SCIENCE
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Murine Regulatory T Cells Contain Hyperproliferative and Death-Prone Subsets with Differential ICOS Expression
- (2012) Y. Chen et al. JOURNAL OF IMMUNOLOGY
- The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
- (2012) S. B. Willingham et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD47-signal regulatory protein- (SIRP ) interactions form a barrier for antibody-mediated tumor cell destruction
- (2011) X. W. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
- (2010) Mark P. Chao et al. CELL
- Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer
- (2010) Zhengbin Shen et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
- (2009) Ravindra Majeti et al. CELL
- OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
- (2008) Silvia Piconese et al. JOURNAL OF EXPERIMENTAL MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now